Oramed Pharma (ORMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 38,310 | 64,016 | 54,007 | 5,618 | -7,642 |
| Depreciation Amortization | 30 | 121 | 91 | 60 | 30 |
| Income taxes - deferred | 9,836 | 7,911 | 7,921 | N/A | N/A |
| Other Working Capital | -1,417 | -1,802 | -2,311 | -4,446 | -1,574 |
| Other Operating Activity | -49,674 | -79,391 | -68,387 | -8,286 | 5,667 |
| Operating Cash Flow | $-2,915 | $-9,145 | $-8,679 | $-7,054 | $-3,519 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -10,082 | 36,521 | 48,950 | 33,499 | 28,450 |
| PPE Investments | -5 | -9 | -7 | -7 | -3 |
| Purchase Of Investment | -999 | -73,886 | -73,695 | -70,821 | -8,444 |
| Sale Of Investment | 3,522 | 45,817 | 31,879 | 8,041 | 3,613 |
| Other Investing Activity | -11,924 | -3,000 | 0 | -1,949 | 0 |
| Investing Cash Flow | $-19,488 | $5,443 | $7,127 | $-31,237 | $23,616 |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | N/A | -4,741 | -732 | -371 | N/A |
| Dividend Paid | -10,364 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $-10,364 | $-4,741 | $-732 | $-371 | $N/A |
| Exchange Rate Effect | 22 | -30 | 43 | 39 | -1 |
| Beginning Cash Position | 45,947 | 54,420 | 54,420 | 54,420 | 54,420 |
| End Cash Position | 13,202 | 45,947 | 52,179 | 15,797 | 74,516 |
| Net Cash Flow | $-32,745 | $-8,473 | $-2,241 | $-38,623 | $20,096 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,915 | -9,145 | -8,679 | -7,054 | -3,519 |
| Capital Expenditure | -5 | -9 | -7 | -7 | -3 |
| Free Cash Flow | -2,920 | -9,154 | -8,686 | -7,061 | -3,522 |